

**Food and Drug Administration
Center for Drug Evaluation and Research**

**Summary Minutes of the
Medical Imaging Drugs Advisory Committee**

July 10, 2000

Holiday Inn
8120 Wisconsin Avenue
Bethesda, MD

Members Present

Laura L. Boles Ponto, Ph.D., Chair
Jonathan M. Links, Ph.D.
Richard J. Hammes, R.Ph.
Mark Tulchinsky, M.D.
Sara J. Abramson, M.D.

FDA Participants

Jay Siegel, M.D.
Karen Weiss, M.D.
Robert Lindblad, M.D.
Lydia Martyneec, M.D.
Chana Fuchs, Ph.D.

Consultants to the GIDAC


Eddie Hoover, M.D.
Thomas Whalen, M.D.
Brent Blumenstein, Ph.D.

Guest Experts to the GIDAC


Robert Rothstein, M.D.
Gary Strange, M.D.

These summary minutes for the July 10, meeting of the Medical Imaging Drugs Advisory Committee were approved on November 6, 2000.

I certify that I attended the July 10, meeting of the Medical Imaging Drugs Advisory Committee and that these minutes accurately reflect what transpired.



Thomas H. Perez, M.P.H., R.Ph.
Executive Secretary



Laura L. Boles Ponto, Ph.D.,
Chair

This report contains public information that has not been reviewed by the agency or the Medical Imaging Drugs Advisory Committee. The official summary minutes will be prepared, circulated, and certified as usual. Transcripts will be available in about 12 days. External requests should be submitted to the Freedom of Information office.

The Medical Imaging Drugs Advisory Committee of the Food and Drug Administration, Center for Drug Evaluation and Research met on July 10, 2000 at the Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

The committee discussed the biologic license application (BLA) 99-1407, Leutech™ (Technetium labeled TC99M anti/CD15 antibody injection), Palatin Technologies Inc., imaging agent as an aid in the diagnosis of equivocal appendicitis.

The Committee had received a briefing document from Palatin Technologies Inc., and the FDA.

There were approximately 30 persons in the audience. The meeting was called to order at 8:30am by the Chair, Laura L. Boles Ponto, Ph.D. Thomas H. Perez, Executive Secretary of the Medical Imaging Drugs Advisory Committee read the Meeting Statement. The Committee members and discussants introduced themselves.

Palatin Technologies Inc., presentation began at 8:45 am and proceeded as follows.

Introduction	Charles Putnam, Chief Operating Officer, Palatin
Description of LeuTech	Terry Smith, Ph. D., Executive Director, Product Development, Palatin
Equivocal Appendicitis	Eric Rypins, M.D. Dept. of Surgery, Tri-City Medical Ctr
Imaging Techniques & Interpretation	Samuel Kipper, M.D. Director Nuclear Medicine, Tri-City Medical Ctr.
Clinical Development Program	Karen McElvany, Ph.D. Director Clinical Affairs, Certus International Inc.
Conclusion	Charles Putnam, Chief Operating Officer, Palatin

At approximately 9:30 the FDA, CBER presentation was made by

Products Review	Chana Fuchs
Nuclear Medicine	Lydia Martynec
Clinical Review	Robert Lindblad

The Open Public Hearing portion of the meeting included one participant, William Wegener, M.D., Ph.D., Vice President of Clinical Research, Immunomedics Inc. Also read at this time were three written statements received by the chair from the following individuals: William A. Hinrichs, M.D., David Haugen, M.D., and Rolf Gulbrandson, M.D.

The Committee discussed the following questions, of which questions 6b and 7 required a vote.

- 1 Characterization of pre-test probability of disease is important for several reasons: a) a test should be evaluated in patients in whom the diagnosis is equivocal; b) a test may perform differently in patients with different probabilities of disease; and c) results may require different interpretation in patients with different pre-test probabilities of disease.

In the phase 3 study under consideration, entry required some suspicion of appendicitis but one or more atypical features.

In future studies of atypical appendicitis, should entry criteria be based principally on physician uncertainty or atypical features? If the latter, please comment on which combination of atypical features would be most useful.

The consensus of the committee was that of atypical features including anorexia.

2. Safety data following LeuTech administration are available on approximately 440 patients (all studies, including ongoing, and for other indications). Of these, approximately 250 comprise the experience in the appendicitis setting. The most frequently reported adverse event in all studies was vasodilatation, which was mild to moderate and did not require intervention. There have been no serious adverse events attributed to the administration of LeuTech. If LeuTech were to lead to serious adverse events in 1 out of 100 patients treated, there is a 1% chance that an event would not be detected in a study of 440 patients. If LeuTech were to result in serious events in as little as 1 in 1000 patients treated, there is a 64% chance that an event would not be detected in a sample size of 250 patients. Estimates of the incidence of appendicitis in the United States are as high as 1 in 500 per year (approximately 600,000 cases per year). Of these, up to 1/3, or approximately 200,000 cases/year, present with atypical signs and symptoms and could potentially be imaged with LeuTech.

Please comment on the adequacy of the safety database given the potential for use of this product in a large patient population.

Adequate for the initial studies. It is desirable to study further; in particular in neutropenic patients, and pediatrics

- 3 The data regarding repeat administration of LeuTech are limited. Since repeat use of a protein product can lead to safety concerns and/or loss of efficacy resulting from antibody formation, if approved, LeuTech would be labeled as a one time administration. However, repeat imaging could be useful for patients who have recurrent abdominal pain atypical for appendicitis. Of 30 normal volunteers enrolled in a readministration study, 5 developed a human anti-mouse antibody (HAMA) response with readministration. None of the 5 had "high" antibody titres (defined by the sponsor as > 1000 ng/ml) and no patient experienced adverse events related to the second administration.

If licensed, should the sponsor be required to generate additional data on repeat imaging as a phase 4 commitment? If so, can these data all be generated in normal volunteers, or should some data also be generated in patients.

Reasonable to request additional data, including HAMA, from tracking current patients.

- 4 The Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (February 28, 1997) recommends "the off site image should be the basis of the definitive analysis of imaging performance in the phase 3 clinical trial." "Off site image interpretation should be performed in as 'blinded' a fashion as possible." In this phase 3 trial, the off site readers were only provided with demographic information (age, sex, weight, height) for each patient. In such a manner one can ensure that the accuracy of reads is influenced by information in the scans, not by other predictive factors such as leukocytosis or physical findings. In actual use, scans may be interpreted in the context of other information.

In addition to the offsite (blinded) and onsite interpretations, is there a value in having offsite physicians read scans after being supplied with clinical information (e.g., presenting signs and symptoms) and/or results of other diagnostic tests?

Although adequate for the study, there is no benefit in offsite interpretation, particularly since leaders are selected for the offsite interpretation.

- 5 For patients who present with atypical signs and symptoms of appendicitis, there is a need for agents that can assist physicians in diagnosing or ruling out appendicitis. In certain subpopulations, especially, women with pelvic inflammatory disease and young children, this need is especially great because other illnesses can confound the diagnosis. Women with coexisting PID were excluded from the phase 3 studies. Forty-eight patients (19 %) were between 10-17 years of age, with 15 (6%) between 5 and 9 years of age, and N= 10 (5%) were > age 65.

- a. **Has the sponsor gathered sufficient data in pediatric and geriatric populations such that, if licensed, the indicated population will be all patients who present with atypical signs and symptoms, without age restriction?**

Although numbers are small there is no reason to justifiably exclude these groups.

- b. **If licensed, should the sponsor be required as a phase 4 commitment to generate data on LeuTech in patient populations, such as women with coexisting PID, patients with other concurrent infections, pediatric patients?**

More data in women would be desirable, particularly since PID would not require surgery. Allow postmarketing surveillance to identify populations adversely affected. Although relatively comfortable with safety, the committee would like to see more efficacy data.

- 6 The phase 3 trial performance data for the aggregate blinded reads, based on the surgeon's pre-scan likelihood estimates, are as follows:

Surgeon's Pre-scan Likelihood Estimate (N)	Incidence of Appendicitis			Sensitivity	Specificity
	total	If scan + (PPV)	If scan - (100%-NPV)		
0-19% (22)	0%	-	-	-	100%
20-39% (61)	15%	86%	6%	67%	98%
40-59% (65)	25%	67%	8%	75%	88%
60-79% (44)	61%	86%	33%	74%	82%
80-100% (8)	88%	100%	50%	86%	100%
<hr/>					
20-79% (170)	31%	79%	11%	73%	92%

- a) **Please comment on whether these data support the ability of LeuTech to aid in the diagnosis of appendicitis. Please comment specifically on its utility to rule in appendicitis and to rule out appendicitis in patients with various levels of pre-test likelihoods.**

Data are supportive.

- b) **Do these data support a determination that LeuTech is safe and effective for use in the diagnosis of appendicitis? If so, please discuss appropriate wording for the Package Insert regarding its clinical use.**

Yes 9 No 0

- 7 The sponsor developed a questionnaire for surgeons designed to evaluate the utility of LeuTech. The surgeons filled out the questionnaire prior to obtaining the LeuTech scan. The surgeons ranked the likelihood of appendicitis, indication for other tests, and patient disposition. After the LeuTech scan results, with instructions to assume the scan result is accurate, the surgeons again filled out the same questionnaire. The shifts in patient management, as reflected by changes in the responses on the questionnaire, were recorded. The shifts in patient management are shown below:

Pre-test plan	N	Post test plan	N	# with appendicitis	%
Send home	43	send home	36	2/36	6%
		observe	2	0/2	0%
		surgery	5	3/5	60%
Observe	113	send home	39	0/39	0%
		observe	43	4/43	9%
		surgery	31	25/31	81%
Surgery	33	send home	5	0/5	0%
		observe	2	0/2	0%
		surgery	26	21/26	81%

Is this approach useful for assessing clinical utility? Do the data generated by the questionnaire support the clinical utility of LeuTech?

Yes 9 No 0

- 8 If licensed, the sponsor will institute a training program for the end users. Ideally, the training program following licensure should be identical to or very similar to the training program utilized in the phase 3 trial. The instruction given to both the Phase 3 and blinded readers in the training program were as follows: " read for highest sensitivity and negative predictive value", " read with mindset of being afraid to miss the diagnosis of appendicitis ".

Please comment on the potential impact of these instructions to the readers in this clinical setting. Is this type of instruction appropriate for a training program?

Favor a voluntary training program.

The meeting was adjourned at 2:30 p.m.